[go: up one dir, main page]

WO2000032778A3 - Methods and compositions for inhibiting neoplastic cell growth - Google Patents

Methods and compositions for inhibiting neoplastic cell growth Download PDF

Info

Publication number
WO2000032778A3
WO2000032778A3 PCT/US1999/028409 US9928409W WO0032778A3 WO 2000032778 A3 WO2000032778 A3 WO 2000032778A3 US 9928409 W US9928409 W US 9928409W WO 0032778 A3 WO0032778 A3 WO 0032778A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
methods
polypeptides
compositions
cell growth
Prior art date
Application number
PCT/US1999/028409
Other languages
French (fr)
Other versions
WO2000032778A2 (en
Inventor
Jian Chen
Audrey Goddard
Austin L Gurney
Kenneth Hillan
Mary Napier
William I Wood
Original Assignee
Genentech Inc
Jian Chen
Audrey Goddard
Austin L Gurney
Kenneth Hillan
Mary Napier
William I Wood
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1998/025108 external-priority patent/WO1999028462A2/en
Application filed by Genentech Inc, Jian Chen, Audrey Goddard, Austin L Gurney, Kenneth Hillan, Mary Napier, William I Wood filed Critical Genentech Inc
Priority to KR1020017006828A priority Critical patent/KR20010086072A/en
Priority to JP2000585409A priority patent/JP2002531092A/en
Priority to IL14267299A priority patent/IL142672A0/en
Priority to EP99965077A priority patent/EP1135491A2/en
Priority to AU31070/00A priority patent/AU3107000A/en
Priority to CA002348157A priority patent/CA2348157A1/en
Priority to IL14321299A priority patent/IL143212A0/en
Priority to MXPA01006345A priority patent/MXPA01006345A/en
Priority to KR1020017007877A priority patent/KR20010102960A/en
Priority to JP2000589694A priority patent/JP2003524390A/en
Priority to CA002353775A priority patent/CA2353775A1/en
Priority to AU21928/00A priority patent/AU2192800A/en
Priority to PCT/US1999/030095 priority patent/WO2000037640A2/en
Priority to EP99966374A priority patent/EP1141289A2/en
Priority to AU25967/00A priority patent/AU2596700A/en
Priority to PCT/US2000/000219 priority patent/WO2000053753A2/en
Priority to PCT/US2000/005004 priority patent/WO2000053757A2/en
Priority to KR1020017011378D priority patent/KR20010104373A/en
Priority to KR1020017011378A priority patent/KR100553300B1/en
Priority to EP00912015A priority patent/EP1159419A1/en
Priority to CA002361849A priority patent/CA2361849A1/en
Priority to JP2000603378A priority patent/JP2003531811A/en
Priority to AU33816/00A priority patent/AU768694B2/en
Priority to CA002362427A priority patent/CA2362427A1/en
Priority to PCT/US2000/005841 priority patent/WO2000053758A2/en
Priority to KR1020017011406A priority patent/KR20010103046A/en
Priority to JP2000603379A priority patent/JP2004516227A/en
Priority to EP00913764A priority patent/EP1220905A2/en
Priority to AU35144/00A priority patent/AU3514400A/en
Priority to PCT/US2000/013705 priority patent/WO2000073445A2/en
Priority to PT00939307T priority patent/PT1212417E/en
Priority to AU54412/00A priority patent/AU5441200A/en
Priority to JP2001500757A priority patent/JP4297317B2/en
Priority to DK00939307T priority patent/DK1212417T3/en
Priority to DE60038740T priority patent/DE60038740T2/en
Priority to CA002376116A priority patent/CA2376116A1/en
Priority to AT00939307T priority patent/ATE393825T1/en
Priority to ES00939307T priority patent/ES2307515T3/en
Priority to EP00939307A priority patent/EP1212417B1/en
Publication of WO2000032778A2 publication Critical patent/WO2000032778A2/en
Priority to PCT/US2000/022031 priority patent/WO2001040464A1/en
Priority to AU69018/00A priority patent/AU6901800A/en
Publication of WO2000032778A3 publication Critical patent/WO2000032778A3/en
Priority to US09/866,028 priority patent/US6642360B2/en
Priority to US09/943,664 priority patent/US20040091972A1/en
Priority to US09/944,403 priority patent/US20020165143A1/en
Priority to US09/944,449 priority patent/US20020102647A1/en
Priority to US09/943,762 priority patent/US20020142958A1/en
Priority to US09/943,780 priority patent/US20030096742A1/en
Priority to US09/944,432 priority patent/US20020142419A1/en
Priority to US09/943,851 priority patent/US20020150976A1/en
Priority to US09/944,396 priority patent/US20020132981A1/en
Priority to US09/944,413 priority patent/US20020156004A1/en
Priority to US09/944,457 priority patent/US6734288B2/en
Priority to US09/944,884 priority patent/US7018837B2/en
Priority to US09/944,852 priority patent/US20030083479A1/en
Priority to US09/944,929 priority patent/US7550573B2/en
Priority to US09/945,015 priority patent/US20020132768A1/en
Priority to US09/944,654 priority patent/US20020142959A1/en
Priority to US09/944,944 priority patent/US6929947B2/en
Priority to US09/944,862 priority patent/US20020115145A1/en
Priority to US09/944,907 priority patent/US20020198147A1/en
Priority to US09/945,584 priority patent/US6908993B2/en
Priority to US09/944,896 priority patent/US7189566B2/en
Priority to US09/945,587 priority patent/US6936254B2/en
Priority to US09/990,456 priority patent/US20020137890A1/en
Priority to US10/028,072 priority patent/US20030004311A1/en
Priority to US10/121,042 priority patent/US20030096386A1/en
Priority to US10/121,051 priority patent/US20030092147A1/en
Priority to US10/121,040 priority patent/US20030082759A1/en
Priority to US10/121,047 priority patent/US20030077778A1/en
Priority to US10/121,059 priority patent/US20030190721A1/en
Priority to US10/121,044 priority patent/US20030190717A1/en
Priority to US10/121,046 priority patent/US20030194791A1/en
Priority to US10/121,041 priority patent/US20030077776A1/en
Priority to US10/121,045 priority patent/US20030073210A1/en
Priority to US10/121,048 priority patent/US20030199051A1/en
Priority to US10/121,063 priority patent/US20030199055A1/en
Priority to US10/121,060 priority patent/US20030190722A1/en
Priority to US10/121,058 priority patent/US20030190720A1/en
Priority to US10/121,062 priority patent/US20030077779A1/en
Priority to US10/121,054 priority patent/US20030199054A1/en
Priority to US10/121,053 priority patent/US20030199053A1/en
Priority to US10/121,043 priority patent/US7220831B2/en
Priority to US10/121,056 priority patent/US20030082760A1/en
Priority to US10/121,057 priority patent/US20030190719A1/en
Priority to US10/121,049 priority patent/US20030022239A1/en
Priority to US10/121,061 priority patent/US20030082761A1/en
Priority to US10/121,050 priority patent/US20030054516A1/en
Priority to US10/121,055 priority patent/US20030190718A1/en
Priority to US10/121,052 priority patent/US20030199052A1/en
Priority to US10/123,156 priority patent/US20030194792A1/en
Priority to US10/123,109 priority patent/US20030190723A1/en
Priority to US10/123,261 priority patent/US20030068796A1/en
Priority to US10/123,215 priority patent/US7291329B2/en
Priority to US10/123,213 priority patent/US7193048B2/en
Priority to US10/123,214 priority patent/US7343721B2/en
Priority to US10/123,155 priority patent/US20030068794A1/en
Priority to US10/123,236 priority patent/US20030068795A1/en
Priority to US10/123,212 priority patent/US7276577B2/en
Priority to US10/123,262 priority patent/US20030049816A1/en
Priority to US10/123,157 priority patent/US20030190725A1/en
Priority to US10/123,235 priority patent/US20030082762A1/en
Priority to US10/123,154 priority patent/US20030190724A1/en
Priority to US10/123,213 priority patent/US20030199057A1/en
Priority to US10/123,771 priority patent/US20030199060A1/en
Priority to US10/123,291 priority patent/US20030199058A1/en
Priority to US10/123,322 priority patent/US20030199059A1/en
Priority to US10/123,108 priority patent/US7635478B2/en
Priority to US10/123,292 priority patent/US20030073211A1/en
Priority to US10/123,907 priority patent/US7084258B2/en
Priority to US10/123,905 priority patent/US20030087344A1/en
Priority to US10/123,905 priority patent/US7285625B2/en
Priority to US10/123,912 priority patent/US20030100087A1/en
Priority to US10/123,908 priority patent/US7335728B2/en
Priority to US10/123,903 priority patent/US20030073212A1/en
Priority to US10/123,913 priority patent/US20030203462A1/en
Priority to US10/123,909 priority patent/US7193049B2/en
Priority to US10/123,911 priority patent/US7408032B2/en
Priority to US10/123,910 priority patent/US7329404B2/en
Priority to US10/123,904 priority patent/US20030022328A1/en
Priority to US10/123,906 priority patent/US20030190726A1/en
Priority to US10/123,902 priority patent/US20030077781A1/en
Priority to US10/124,820 priority patent/US20030190729A1/en
Priority to US10/124,822 priority patent/US7109305B2/en
Priority to US10/124,821 priority patent/US20030199023A1/en
Priority to US10/124,824 priority patent/US20030077659A1/en
Priority to US10/124,818 priority patent/US20030082763A1/en
Priority to US10/125,795 priority patent/US7304131B2/en
Priority to US10/124,823 priority patent/US20030199062A1/en
Priority to US10/125,704 priority patent/US7357926B2/en
Priority to US10/124,814 priority patent/US7105335B2/en
Priority to US10/124,819 priority patent/US7285626B2/en
Priority to US10/125,805 priority patent/US20030194794A1/en
Priority to US10/124,817 priority patent/US20030077786A1/en
Priority to US10/124,813 priority patent/US7312307B2/en
Priority to US10/124,816 priority patent/US20030190728A1/en
Priority to US10/125,927 priority patent/US20030190731A1/en
Priority to US10/125,932 priority patent/US7317079B2/en
Priority to US10/125,931 priority patent/US20030199063A1/en
Priority to US10/125,922 priority patent/US7309762B2/en
Priority to US10/125,924 priority patent/US7342097B2/en
Priority to US10/127,831 priority patent/US20030082689A1/en
Priority to US10/128,689 priority patent/US20030087365A1/en
Priority to US10/131,817 priority patent/US7291701B2/en
Priority to US10/131,823 priority patent/US7304132B2/en
Priority to US10/131,825 priority patent/US7282566B2/en
Priority to US10/137,867 priority patent/US20030207349A1/en
Priority to US10/137,865 priority patent/US20030032155A1/en
Priority to US10/137,868 priority patent/US20030082764A1/en
Priority to US10/140,470 priority patent/US20030022331A1/en
Priority to US10/139,980 priority patent/US7247710B2/en
Priority to US10/139,963 priority patent/US7288625B2/en
Priority to US10/140,474 priority patent/US20030032156A1/en
Priority to US10/140,020 priority patent/US20030207415A1/en
Priority to US10/140,024 priority patent/US20040058424A1/en
Priority to US10/140,023 priority patent/US20030207416A1/en
Priority to US10/140,921 priority patent/US7317080B2/en
Priority to US10/140,808 priority patent/US7425621B2/en
Priority to US10/140,805 priority patent/US20030207417A1/en
Priority to US10/140,809 priority patent/US20030207418A1/en
Priority to US10/140,928 priority patent/US20030068798A1/en
Priority to US10/140,925 priority patent/US20030073215A1/en
Priority to US10/140,860 priority patent/US7307151B2/en
Priority to US10/140,864 priority patent/US20030207419A1/en
Priority to US10/140,865 priority patent/US20030207420A1/en
Priority to US10/141,701 priority patent/US20030207421A1/en
Priority to US10/141,756 priority patent/US7488586B2/en
Priority to US10/141,754 priority patent/US7361732B2/en
Priority to US10/141,755 priority patent/US7297764B2/en
Priority to US10/141,760 priority patent/US7342104B2/en
Priority to US10/142,417 priority patent/US7304133B2/en
Priority to US10/142,425 priority patent/US20030207424A1/en
Priority to US10/143,113 priority patent/US7329730B2/en
Priority to US10/142,430 priority patent/US7309766B2/en
Priority to US10/143,114 priority patent/US20030036180A1/en
Priority to US10/142,423 priority patent/US20030049817A1/en
Priority to US10/142,431 priority patent/US7285629B2/en
Priority to US10/142,419 priority patent/US7153941B2/en
Priority to US10/143,032 priority patent/US7408033B2/en
Priority to US10/146,730 priority patent/US20030207427A1/en
Priority to US10/146,792 priority patent/US20030207428A1/en
Priority to US10/147,528 priority patent/US20030219885A1/en
Priority to US10/147,519 priority patent/US20030077791A1/en
Priority to US10/147,492 priority patent/US20030082765A1/en
Priority to US10/147,536 priority patent/US20040077064A1/en
Priority to US10/152,395 priority patent/US7189534B2/en
Priority to US10/153,934 priority patent/US20030129695A1/en
Priority to US10/156,843 priority patent/US20030207805A1/en
Priority to US10/157,782 priority patent/US20030077792A1/en
Priority to US10/157,786 priority patent/US20030208055A1/en
Priority to US10/158,791 priority patent/US20030207429A1/en
Priority to US10/160,498 priority patent/US20030073216A1/en
Priority to US10/158,782 priority patent/US20030082766A1/en
Priority to US10/176,913 priority patent/US20030022298A1/en
Priority to US10/187,885 priority patent/US20030032138A1/en
Priority to US10/429,667 priority patent/US20030207401A1/en
Priority to US10/735,014 priority patent/US7442772B2/en
Priority to JP2003420475A priority patent/JP2004154140A/en
Priority to US10/943,353 priority patent/US20050059115A1/en
Priority to US11/296,155 priority patent/US20060127983A1/en
Priority to US11/341,175 priority patent/US7468427B2/en
Priority to US12/079,178 priority patent/US20090170158A1/en
Priority to JP2008145176A priority patent/JP2009019032A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention concerns methods and compositions for inhibiting neoplastic cell growth. In particular, the present invention concerns antitumor compositions and methods for the treatment of tumors. The invention further concerns screening methods for identifying growth inhibitory, e.g., antitumor compounds. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
PCT/US1999/028409 1997-03-31 1999-11-30 Methods and compositions for inhibiting neoplastic cell growth WO2000032778A2 (en)

Priority Applications (202)

Application Number Priority Date Filing Date Title
KR1020017006828A KR20010086072A (en) 1998-12-01 1999-11-30 Methods and Compositions for Inhibiting Neoplastic Cell Growth
JP2000585409A JP2002531092A (en) 1998-12-01 1999-11-30 Compositions and methods for inhibiting neoplastic cell growth
IL14267299A IL142672A0 (en) 1998-12-01 1999-11-30 Methods and compositions for inhibiting neoplastic cell growth
EP99965077A EP1135491A2 (en) 1998-12-01 1999-11-30 Methods and compositions for inhibiting neoplastic cell growth
AU31070/00A AU3107000A (en) 1998-12-01 1999-11-30 Methods and compositions for inhibiting neoplastic cell growth
CA002348157A CA2348157A1 (en) 1998-12-01 1999-11-30 Methods and compositions for inhibiting neoplastic cell growth
IL14321299A IL143212A0 (en) 1998-12-22 1999-12-16 Compositions and methods for the treatment of tumor
MXPA01006345A MXPA01006345A (en) 1998-12-22 1999-12-16 Compositions and methods for the treatment of tumor.
KR1020017007877A KR20010102960A (en) 1998-12-22 1999-12-16 Compositions and Methods for The Treatment of Tumor
JP2000589694A JP2003524390A (en) 1998-12-22 1999-12-16 Compositions and methods for treating tumors
CA002353775A CA2353775A1 (en) 1998-12-22 1999-12-16 Compositions and methods for the treatment of tumor
AU21928/00A AU2192800A (en) 1998-12-22 1999-12-16 Compositions and methods for the treatment of tumor
PCT/US1999/030095 WO2000037640A2 (en) 1998-12-22 1999-12-16 Compositions and methods for the treatment of tumor
EP99966374A EP1141289A2 (en) 1998-12-22 1999-12-16 Compositions and method for the treatement of tumors
AU25967/00A AU2596700A (en) 1999-03-08 1999-12-30 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US2000/000219 WO2000053753A2 (en) 1999-03-08 2000-01-05 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US2000/005004 WO2000053757A2 (en) 1999-03-08 2000-02-24 Promotion or inhibition of angiogenesis and cardiovascularization
KR1020017011378D KR20010104373A (en) 1999-03-08 2000-02-24 Promotion or Inhibition of Angiogenesis and Cardiovascularization
KR1020017011378A KR100553300B1 (en) 1999-03-08 2000-02-24 Methods to promote or inhibit angiogenesis and cardiovascularization
EP00912015A EP1159419A1 (en) 1999-03-08 2000-02-24 Promotion or inhibition of angiogenesis and cardiovascularization
CA002361849A CA2361849A1 (en) 1999-03-08 2000-02-24 Promotion or inhibition of angiogenesis and cardiovascularization
JP2000603378A JP2003531811A (en) 1999-03-08 2000-02-24 Promotion or inhibition of angiogenesis and cardiovascularization
AU33816/00A AU768694B2 (en) 1999-03-08 2000-02-24 Promotion or inhibition of angiogenesis and cardiovascularization
CA002362427A CA2362427A1 (en) 1999-03-08 2000-03-02 Compositions and methods for the treatment of immune related diseases
PCT/US2000/005841 WO2000053758A2 (en) 1999-03-08 2000-03-02 Compositions and methods for the treatment of immune related diseases
KR1020017011406A KR20010103046A (en) 1999-03-08 2000-03-02 Compositions and Methods for the Treatment of Immune Related Diseases
JP2000603379A JP2004516227A (en) 1999-03-08 2000-03-02 Compositions and methods for treating immune-related diseases
EP00913764A EP1220905A2 (en) 1999-03-08 2000-03-02 Composition and methods for the treatment of immune related diseases
AU35144/00A AU3514400A (en) 1999-03-08 2000-03-02 Compositions and methods for the treatment of immune related diseases
PCT/US2000/013705 WO2000073445A2 (en) 1999-06-02 2000-05-17 Interleukin-1-receptor associated kinase-3 (irak3)
PT00939307T PT1212417E (en) 1999-06-02 2000-05-17 Promotion or inhibition of angiogenesis and cardiovascularization
AU54412/00A AU5441200A (en) 1999-06-02 2000-05-17 Promotion or inhibition of angiogenesis and cardiovascularization
JP2001500757A JP4297317B2 (en) 1999-06-02 2000-05-17 Promotion or inhibition of angiogenesis and cardiovascularization
DK00939307T DK1212417T3 (en) 1999-06-02 2000-05-17 Promotion or inhibition of angiogenesis and vascularization
DE60038740T DE60038740T2 (en) 1999-06-02 2000-05-17 Stimulation or inhibition of angiogenesis and cardiovascularisation
CA002376116A CA2376116A1 (en) 1999-06-02 2000-05-17 Promotion or inhibition of angiogenesis and cardiovascularization
AT00939307T ATE393825T1 (en) 1999-06-02 2000-05-17 STIMULATION OR INHIBITION OF ANGIOGENESIS AND CARDIAC VASCULARIZATION
ES00939307T ES2307515T3 (en) 1999-06-02 2000-05-17 ACTIVATION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION.
EP00939307A EP1212417B1 (en) 1999-06-02 2000-05-17 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US2000/022031 WO2001040464A1 (en) 1999-11-30 2000-08-11 Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
AU69018/00A AU6901800A (en) 1999-11-30 2000-08-11 Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
US09/866,028 US6642360B2 (en) 1997-12-03 2001-05-25 Secreted polypeptides that stimulate release of proteoglycans from cartilage
US09/943,664 US20040091972A1 (en) 1997-12-03 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,403 US20020165143A1 (en) 1997-12-03 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,449 US20020102647A1 (en) 1997-12-03 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/943,762 US20020142958A1 (en) 1998-09-16 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/943,780 US20030096742A1 (en) 1997-12-03 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,432 US20020142419A1 (en) 1998-09-16 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/943,851 US20020150976A1 (en) 1997-12-03 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,396 US20020132981A1 (en) 1997-12-03 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,413 US20020156004A1 (en) 1998-09-16 2001-08-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,457 US6734288B2 (en) 1997-12-03 2001-08-30 Antibodies against a secreted polypeptide that stimulates release of proteoglycans from cartilage
US09/944,884 US7018837B2 (en) 1997-12-03 2001-08-31 Nucleic acids encoding secreted polypeptides that stimulate release of proteoglycans from cartilage
US09/944,852 US20030083479A1 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,929 US7550573B2 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/945,015 US20020132768A1 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,654 US20020142959A1 (en) 1998-09-16 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,944 US6929947B2 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,862 US20020115145A1 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,907 US20020198147A1 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/945,584 US6908993B2 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/944,896 US7189566B2 (en) 1997-12-03 2001-08-31 PRO347 nucleic acids
US09/945,587 US6936254B2 (en) 1997-12-03 2001-08-31 Method of inducing fetal hemoglobin synthesis
US09/990,456 US20020137890A1 (en) 1997-03-31 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/028,072 US20030004311A1 (en) 1997-06-18 2001-12-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,042 US20030096386A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,051 US20030092147A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,040 US20030082759A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,047 US20030077778A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,059 US20030190721A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,044 US20030190717A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,046 US20030194791A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,041 US20030077776A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,045 US20030073210A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,048 US20030199051A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,063 US20030199055A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,060 US20030190722A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,058 US20030190720A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,062 US20030077779A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,054 US20030199054A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,053 US20030199053A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,043 US7220831B2 (en) 1997-03-31 2002-04-12 PRO235 polypeptides
US10/121,056 US20030082760A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,057 US20030190719A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,049 US20030022239A1 (en) 1997-06-18 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,061 US20030082761A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,050 US20030054516A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,055 US20030190718A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,052 US20030199052A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,156 US20030194792A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,109 US20030190723A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,261 US20030068796A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,215 US7291329B2 (en) 1997-03-31 2002-04-15 Antibodies against PRO4406
US10/123,213 US7193048B2 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,214 US7343721B2 (en) 1997-03-31 2002-04-15 PRO4406 polypeptide
US10/123,155 US20030068794A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,236 US20030068795A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,212 US7276577B2 (en) 1997-03-31 2002-04-15 PRO1866 polypeptides
US10/123,262 US20030049816A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,157 US20030190725A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,235 US20030082762A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,154 US20030190724A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,213 US20030199057A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,771 US20030199060A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,291 US20030199058A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,322 US20030199059A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,108 US7635478B2 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,292 US20030073211A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,907 US7084258B2 (en) 1997-03-31 2002-04-16 Antibodies against the PRO862 polypeptides
US10/123,905 US20030087344A1 (en) 1997-06-18 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,905 US7285625B2 (en) 1997-06-18 2002-04-16 PRO536 polypeptides
US10/123,912 US20030100087A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,908 US7335728B2 (en) 1997-03-31 2002-04-16 PRO1310 polypeptides
US10/123,903 US20030073212A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,913 US20030203462A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,909 US7193049B2 (en) 1997-03-31 2002-04-16 PRO862 polypeptides
US10/123,911 US7408032B2 (en) 1997-03-31 2002-04-16 PRO1188 polypeptides
US10/123,910 US7329404B2 (en) 1997-03-31 2002-04-16 Antibodies against PRO1310
US10/123,904 US20030022328A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,906 US20030190726A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,902 US20030077781A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,820 US20030190729A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,822 US7109305B2 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,821 US20030199023A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,824 US20030077659A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,818 US20030082763A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,795 US7304131B2 (en) 1997-03-31 2002-04-17 PRO1483 polypeptides
US10/124,823 US20030199062A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,704 US7357926B2 (en) 1997-03-31 2002-04-17 Antibodies against PRO1879 and the use thereof
US10/124,814 US7105335B2 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,819 US7285626B2 (en) 1997-03-31 2002-04-17 PRO1076 polypeptides
US10/125,805 US20030194794A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,817 US20030077786A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,813 US7312307B2 (en) 1997-03-31 2002-04-17 PRO1056 polypeptides
US10/124,816 US20030190728A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,927 US20030190731A1 (en) 1997-03-31 2002-04-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,932 US7317079B2 (en) 1997-03-31 2002-04-19 PRO812 polypeptides
US10/125,931 US20030199063A1 (en) 1997-03-31 2002-04-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,922 US7309762B2 (en) 1997-03-31 2002-04-19 PRO1360 polypeptides
US10/125,924 US7342097B2 (en) 1997-03-31 2002-04-19 PRO1309 polypeptides
US10/127,831 US20030082689A1 (en) 1997-03-31 2002-04-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/128,689 US20030087365A1 (en) 1997-03-31 2002-04-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/131,817 US7291701B2 (en) 1997-03-31 2002-04-24 PRO1777 polypeptides
US10/131,823 US7304132B2 (en) 1997-03-31 2002-04-24 PRO1693 polypeptides
US10/131,825 US7282566B2 (en) 1997-03-31 2002-04-24 PRO1779 polypeptide
US10/137,867 US20030207349A1 (en) 1997-03-31 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/137,865 US20030032155A1 (en) 1997-03-31 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/137,868 US20030082764A1 (en) 1997-03-31 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,470 US20030022331A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/139,980 US7247710B2 (en) 1997-03-31 2002-05-06 PRO4395 antibodies
US10/139,963 US7288625B2 (en) 1997-03-31 2002-05-06 PRO4395 polypeptides
US10/140,474 US20030032156A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,020 US20030207415A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,024 US20040058424A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,023 US20030207416A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,921 US7317080B2 (en) 1997-03-31 2002-05-07 PRO4303 polypeptides
US10/140,808 US7425621B2 (en) 1997-03-31 2002-05-07 Antibodies against the PRO4401 polypeptide
US10/140,805 US20030207417A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,809 US20030207418A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,928 US20030068798A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,925 US20030073215A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,860 US7307151B2 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,864 US20030207419A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,865 US20030207420A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/141,701 US20030207421A1 (en) 1997-03-31 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/141,756 US7488586B2 (en) 1997-03-31 2002-05-08 PRO4409 polypeptides
US10/141,754 US7361732B2 (en) 1997-03-31 2002-05-08 PRO4400 polypeptides
US10/141,755 US7297764B2 (en) 1997-03-31 2002-05-08 PRO4318 polypeptides
US10/141,760 US7342104B2 (en) 1997-03-31 2002-05-08 Antibodies against the PRO4320 polypeptide
US10/142,417 US7304133B2 (en) 1997-03-31 2002-05-09 PRO4389 polypeptides
US10/142,425 US20030207424A1 (en) 1997-03-31 2002-05-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/143,113 US7329730B2 (en) 1997-03-31 2002-05-09 PRO4348 polypeptides
US10/142,430 US7309766B2 (en) 1997-03-31 2002-05-09 PRO5774 polypeptides
US10/143,114 US20030036180A1 (en) 1997-03-31 2002-05-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/142,423 US20030049817A1 (en) 1997-03-31 2002-05-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/142,431 US7285629B2 (en) 1997-03-31 2002-05-10 Pro5005 polypeptides
US10/142,419 US7153941B2 (en) 1997-03-31 2002-05-10 Antibodies that bind PRO4994 polypeptides
US10/143,032 US7408033B2 (en) 1997-03-31 2002-05-10 PRO5995 polypeptides
US10/146,730 US20030207427A1 (en) 1997-03-31 2002-05-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/146,792 US20030207428A1 (en) 1997-03-31 2002-05-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,528 US20030219885A1 (en) 1997-03-31 2002-05-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,519 US20030077791A1 (en) 1997-03-31 2002-05-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,492 US20030082765A1 (en) 1997-03-31 2002-05-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,536 US20040077064A1 (en) 1997-03-31 2002-05-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/152,395 US7189534B2 (en) 1997-03-31 2002-05-21 PRO4320 polynucleotide
US10/153,934 US20030129695A1 (en) 1997-03-31 2002-05-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/156,843 US20030207805A1 (en) 1997-06-18 2002-05-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/157,782 US20030077792A1 (en) 1997-03-31 2002-05-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/157,786 US20030208055A1 (en) 1997-03-31 2002-05-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/158,791 US20030207429A1 (en) 1997-03-31 2002-05-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/160,498 US20030073216A1 (en) 1997-03-31 2002-05-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/158,782 US20030082766A1 (en) 1997-03-31 2002-05-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,913 US20030022298A1 (en) 1997-09-15 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,885 US20030032138A1 (en) 1998-06-24 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/429,667 US20030207401A1 (en) 1997-12-03 2003-05-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/735,014 US7442772B2 (en) 1997-12-03 2003-12-12 Antibodies to PRO361 polypeptide
JP2003420475A JP2004154140A (en) 1999-03-08 2003-12-18 Promotion or inhibition of angioplasty and cardiovascular neogenesis
US10/943,353 US20050059115A1 (en) 1997-12-03 2004-09-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/296,155 US20060127983A1 (en) 1997-12-03 2005-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/341,175 US7468427B2 (en) 1997-03-31 2006-01-27 Antibodies to PRO1275 polypeptide
US12/079,178 US20090170158A1 (en) 1997-12-03 2008-03-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2008145176A JP2009019032A (en) 1999-06-02 2008-06-02 Promotion or inhibition of angiogenesis and cardiovascularization

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
PCT/US1998/025108 WO1999028462A2 (en) 1997-12-03 1998-12-01 Polypeptides and nucleic acids encoding the same
USPCT/US98/25108 1998-12-01
US11285098P 1998-12-16 1998-12-16
US60/112,850 1998-12-16
US11329698P 1998-12-22 1998-12-22
US60/113,296 1998-12-22
US14475899P 1999-07-20 1999-07-20
US60/144,758 1999-07-20
US14569899P 1999-07-26 1999-07-26
US60/145,698 1999-07-26

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US21602198A Continuation 1997-12-03 1998-12-16
PCT/US1999/021090 Continuation WO2000015796A2 (en) 1994-09-08 1999-09-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Related Child Applications (4)

Application Number Title Priority Date Filing Date
PCT/US1999/028313 Continuation WO2000032221A2 (en) 1994-09-08 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US1999/028301 Continuation-In-Part WO2000032776A2 (en) 1994-09-08 1999-12-01 Secreted amd transmembrane polypeptides and nucleic acids encoding the same
US09/866,028 Continuation-In-Part US6642360B2 (en) 1996-11-06 2001-05-25 Secreted polypeptides that stimulate release of proteoglycans from cartilage
US09/944,862 Continuation US20020115145A1 (en) 1997-12-03 2001-08-31 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Publications (2)

Publication Number Publication Date
WO2000032778A2 WO2000032778A2 (en) 2000-06-08
WO2000032778A3 true WO2000032778A3 (en) 2000-10-19

Family

ID=56289976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/028409 WO2000032778A2 (en) 1997-03-31 1999-11-30 Methods and compositions for inhibiting neoplastic cell growth

Country Status (6)

Country Link
EP (1) EP1135491A2 (en)
JP (1) JP2002531092A (en)
KR (1) KR20010086072A (en)
AU (1) AU3107000A (en)
CA (1) CA2348157A1 (en)
WO (1) WO2000032778A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3492999B2 (en) 1997-08-26 2004-02-03 ザイモジェネティクス，インコーポレイティド Homologs of adipocyte-specific proteins
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
JP2007518399A (en) * 2003-12-02 2007-07-12 ジェンザイム コーポレイション Compositions and methods for diagnosing and treating lung cancer
TW201605896A (en) 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins
EP3151921B1 (en) 2014-06-06 2019-08-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
EA201792497A1 (en) 2015-06-03 2018-05-31 Бристол-Майерс Сквибб Компани ANTIBODIES TO GITR FOR DIAGNOSIS OF MALIGNANT TUMOR
ES2926969T3 (en) 2015-11-19 2022-10-31 Bristol Myers Squibb Co Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and uses thereof
EP3625260A1 (en) 2017-05-16 2020-03-25 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3325131A1 (en) * 1982-07-12 1984-01-12 Damon Biotech, Inc., 02194 Needham Heights, Mass. INTERFERON E AND ITS PRODUCTION AND PHARMACEUTICAL USE
GB2161487A (en) * 1984-07-06 1986-01-15 Damon Biotech Inc Interferon epsilon
EP0315289A2 (en) * 1987-11-06 1989-05-10 Oncogen Cell growth inhibitory factor
WO1991015510A1 (en) * 1990-04-03 1991-10-17 Bristol-Myers Squibb Company Epithelins: novel cysteine - rich growth modulating proteins
WO1995009005A1 (en) * 1993-09-29 1995-04-06 Bristol-Myers Squibb Company Methods for stimulating interleukin-6 synthesis and inducing thrombocytopoiesis using oncostatin m
WO1999029863A1 (en) * 1997-12-08 1999-06-17 Genentech, Inc. Human interferon-epsilon: a type i interferon

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3325131A1 (en) * 1982-07-12 1984-01-12 Damon Biotech, Inc., 02194 Needham Heights, Mass. INTERFERON E AND ITS PRODUCTION AND PHARMACEUTICAL USE
GB2161487A (en) * 1984-07-06 1986-01-15 Damon Biotech Inc Interferon epsilon
EP0315289A2 (en) * 1987-11-06 1989-05-10 Oncogen Cell growth inhibitory factor
WO1991015510A1 (en) * 1990-04-03 1991-10-17 Bristol-Myers Squibb Company Epithelins: novel cysteine - rich growth modulating proteins
WO1995009005A1 (en) * 1993-09-29 1995-04-06 Bristol-Myers Squibb Company Methods for stimulating interleukin-6 synthesis and inducing thrombocytopoiesis using oncostatin m
WO1999029863A1 (en) * 1997-12-08 1999-06-17 Genentech, Inc. Human interferon-epsilon: a type i interferon

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M D ADAMS ET AL: "Use of e random human BAC end sequence database for sequence-ready map Building", EMBL NUCLEOTIDE SEQU, 4 September 1998 (1998-09-04), XP002101135 *

Also Published As

Publication number Publication date
KR20010086072A (en) 2001-09-07
EP1135491A2 (en) 2001-09-26
AU3107000A (en) 2000-06-19
JP2002531092A (en) 2002-09-24
WO2000032778A2 (en) 2000-06-08
CA2348157A1 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
WO2000037638A3 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2000073348A3 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2002026822A3 (en) Pumpcn compositions and uses thereof
WO1999060127A3 (en) Il-17 homologous polypeptides and therapeutic uses thereof
HK1114636A1 (en) 1l-17 homologous polypeptides and therapeutic uses thereof
WO1999061469A3 (en) Prostate growth-associated membrane proteins
EP1690872A3 (en) Composition and methods for the diagnosis of tumours
WO1999028462A3 (en) Polypeptides and nucleic acids encoding the same
WO2001007611A3 (en) Novel polynucleotides and method for the use thereof
WO2000032778A3 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2001049715A3 (en) Methods and compositions for inhibiting neoplastic cell growth
WO2000037640A3 (en) Compositions and methods for the treatment of tumor
WO2002016611A3 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
WO2000039297A3 (en) Il-1 related polypeptides
EP2075335A3 (en) Methods and compositions for inhibiting neoplastic cell growth
EP1873244A8 (en) Methods and compositions for inhibiting neoplastic cell growth
KR100515858B1 (en) PRO617 Polypeptides
EP1241179A3 (en) Human cornichon-like protein and nucleic acids encoding it
EP1241250A3 (en) Human dehydrogenase-like protein and nucleic acid encoding it
KR100515857B1 (en) PRO792 Polypeptides
EP1241187A3 (en) Fibilin-like polypeptide and nucleic acids encoding the same
KR100515856B1 (en) PRO618 Polypeptides
KR100515855B1 (en) PRO351 Polypeptides
EP1251139A3 (en) Human mindin-like protein and nucleic acids encoding it
EP1241186A3 (en) Human growth arrest specific gene 6 (gas-6) and nucleic acids encoding the same

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 1999 254311

Country of ref document: US

Date of ref document: 19990303

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 142672

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2348157

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 511348

Country of ref document: NZ

Ref document number: 31070/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999965077

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200103883

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/A/2001/005418

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 585409

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017006828

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020017006828

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999965077

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1020017006828

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999965077

Country of ref document: EP